Background: Intracytoplasmic lumina (ICL) are observed in several cancers, including urothelial carcinoma (UC). We have reported that ICL in urine cytology (cICL) is more frequent in high-grade UCs than in low-grade UCs; however, the correlation between the presence of ICL and prognosis is unclear. Objectives: The aim of this work was to determine the association between cICL and prognosis in bladder cancer. Method: We retrospectively investigated 87 patients with bladder cancer who received a histological diagnosis within 3 months of urine cytology at Kanazawa Medical University between 2003 and 2007. The cytological diagnosis and the number of cICL, histological diagnosis, tumor grade or variant, pT stage, ICL in histological specimens, and immunohistochemistry for mucins were evaluated. Data on the treatment type, recurrence, survival, cause of death, and length of follow-up were collected from electronic medical records. Results: Muscle invasion, high-grade UC, lymph node metastasis, distant metastasis, adjuvant therapy, and disease-related mortality were more frequent in patients with cICL-positive bladder cancer than in those without cICL-positive bladder cancer. Immunohistochemistry revealed the expression of Muc-1 and Muc-4 in patients with cICL-positive bladder cancer. Univariate analysis revealed that cytological diagnosis by the Paris system and the 2015 version of the Japanese reporting system, muscle invasion, high-grade UC, lymph node metastasis, distant metastasis, and adjuvant chemotherapy and/or radiotherapy were significant factors associated with prognosis. Furthermore, survival was shorter in patients with cICL-positive non-muscle-invasive bladder cancer than in those with cICL-negative non-muscle-invasive bladder cancer. In the multivariate analysis, only distant metastasis was significantly associated with survival. Conclusions: cICL predicted shorter survival in patients with non-muscle-invasive bladder cancer, suggesting that ICL is one of the important diagnostic features of high-grade UC with a worse prognosis in urine cytology.

1.
Rosenthal
DL
,
Wojcik
EM
,
Kurtycz
DF
, editors
.
The Paris System for Reporting Urinary Cytology
.
Springer Nature
;
2016
.
2.
Shiraishi
T
,
Ohtani
H
,
Kinjo
M
,
Korematsu
M
,
Mimura
A
, editors
.
The 2015 Japan Reporting System for Urinary Cytology
. 1st ed.
The Japanese Society of Clinical Cytology
;
2016
., Available from jscc.or.jp/wp-content/themes/jscc/zassi/55-4yp/55-4-06
3.
Donhuijsen
K
,
Schmidt
U
,
Richter
HJ
,
Leder
LD
.
Mucoid cytoplasmic inclusions in urothelial carcinomas
.
Hum Pathol
.
1992
Aug
;
23
(
8
):
860
4
.
[PubMed]
0046-8177
4.
Delladetsima
J
,
Antonakopoulos
GN
,
Dapolla
V
,
Kittas
C
.
Intraepithelial lumina in urothelial bladder neoplasms. A histochemical, immunohistochemical and electron microscopy study
.
APMIS
.
1989
May
;
97
(
5
):
406
12
.
[PubMed]
1600-0463
5.
Guan
H
,
Tatsas
AD
,
Ali
SZ
.
Signet ring cell carcinoma in urine cytology: cytomorphologic findings and differential diagnosis
.
Acta Cytol
.
2012
;
56
(
2
):
177
82
.
[PubMed]
0001-5547
6.
Ohtsuki
Y
,
Fukumoto
T
,
Okada
Y
,
Teratani
Y
,
Hayashi
Y
,
Lee
GH
, et al
Immunohistochemical and ultrastructural characterization of the signet-ring cell carcinoma component in a case of urothelial carcinoma of the urinary bladder
.
Med Mol Morphol
.
2010
Jun
;
43
(
2
):
96
101
.
[PubMed]
1860-1480
7.
Sato
K
,
Ueda
Y
,
Kawamura
K
,
Aihara
K
,
Katsuda
S
.
Plasmacytoid urothelial carcinoma of the urinary bladder: a case report and immunohistochemical study
.
Pathol Res Pract
.
2009
;
205
(
3
):
189
94
.
[PubMed]
0344-0338
8.
Terauchi
T
,
Sato
K
,
Takenaka
M
,
Yamashita
M
,
Asakura
Y
,
Nakano
M
, et al
Intracytoplasmic lumina of urothelial carcinoma in urine cytology
.
J Japanese Soc Clin Cytol
.
2009
;
48
(
1
):
12
6
.
9.
Moch
H
,
Humphrey
PA
,
Ulbright
TM
,
Reuter
VE
, editors
.
WHO classification of tumours of the urinarl tract
; in : WHO classification of tumours of the urinary system and male genital organs, 1st ed. Lyon: the International Agency for Research on Cancer;
2016
, pp 78-79.
10.
Kanda
Y
.
Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
.
Bone Marrow Transplant
.
2013
Mar
;
48
(
3
):
452
8
.
[PubMed]
0268-3369
11.
Bartosch
C
,
Mendes
N
,
Rios
E
,
Rodrigues
M
,
Eloy
C
,
Reis
CA
, et al
Morphological features and mucin expression profile of breast carcinomas with signet-ring cell differentiation
.
Pathol Res Pract
.
2015
Aug
;
211
(
8
):
588
95
.
[PubMed]
0344-0338
12.
Kao
YC
,
Fang
WL
,
Wang
RF
,
Li
AF
,
Yang
MH
,
Wu
CW
, et al
Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer
.
Gastric Cancer
.
2019
Mar
;
22
(
2
):
255
63
.
[PubMed]
1436-3291
13.
Kaur
S
,
Momi
N
,
Chakraborty
S
,
Wagner
DG
,
Horn
AJ
,
Lele
SM
, et al
Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis
.
PLoS One
.
2014
Mar
;
9
(
3
):
e92742
.
[PubMed]
1932-6203
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.